Washington, DC (February 5, 2020) — The Association for Accessible Medicines (AAM) is the Public Affairs Council Innovations in Public Affairs: 2020 Award Winner in the category of Communications Innovations.
AAM, the trade association representing the manufacturers of generic and biosimilar medicines, was recognized for its celebration of the 35th anniversary of President Ronald Reagan’s September 24, 1984 signing of the Hatch-Waxman Act, which created the modern generic drug industry in America. The association distributed delicious custom-made “Happy 35th Birthday Generics” Georgetown Cupcakes on Capitol Hill to raise awareness for the tremendous benefits generic medicines have provided U.S. patients while publicizing the release of the industry’s annual Access & Savings Report.
“Generic medicines are by their very nature not known for branding so unfortunately we are too often taken for granted. To overcome that inherent challenge, AAM decided to enlist the help of a very strong brand to help drive home with policymakers our message of patient access and savings,” says Allen Goldberg, Senior Vice President of Communications at AAM. “When you have 90% market share – generics fill 9 out of every 10 prescriptions – but relatively little mindshare and are underappreciated, it helps to be creative to remind folks that your products are the solution to high drug prices.”
AAM thanks its creative partners, Dirt Media, Model B and RedPeg Marketing.
Erica Klinger (left), AAM's Senior Director, Marketing accepted the Communications Innovation Award on behalf of AAM at The Advocacy Conference hosted by the Public Affairs Council.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.